David Prewitt
Cardiovascular Disease · Plano, TXNPI 1871580316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,045 and has fallen 97.9% since, to $22 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 179 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$497
- Novartis$486
- Amgen$196
- Heartflow, Inc.$187
- Amarin Pharma, Inc.$170
- Medtronic$158
- plus $1K from 18 others
What the payments were for
- Consulting fees$171%
- Food & beverage$2,74899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $497 |
| Novartis | 29 | $486 |
| Amgen | 16 | $196 |
| Heartflow, Inc. | 2 | $187 |
| Amarin Pharma, Inc. | 10 | $170 |
| Medtronic(2 entities) | 2 | $158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $138 |
| Kowa Pharmaceuticals America, Inc. | 16 | $136 |
| Novo Nordisk | 8 | $117 |
| AstraZeneca | 4 | $79 |
| Abbott | 3 | $74 |
| Esperion Therapeutics, Inc. | 5 | $68 |
| Merck | 4 | $63 |
| Boehringer Ingelheim | 4 | $61 |
| Regeneron Healthcare Solutions, Inc. | 4 | $53 |
| Pfizer | 4 | $53 |
| Arbor Pharmaceuticals, Inc. | 4 | $48 |
| Boston Scientific | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Itamar Medical Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,765 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- Sahil BakshiPlano$167K
- David RawitscherPlano$122K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.